[CNAT] Conatus Pharmaceuticals Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For CNAT
CNAT is in the medium-term down -11% below S&P in 2 years and down -74% in 3 years. In the long-term down -95% below S&P in 5 years and down -99% below S&P in 11 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -71.33% | ROE | -82.04% | ROI | ||
| Current Ratio | 10.09 | Quick Ratio | Long Term Debt/Equity | 0.04 | Debt Ratio | 0.11 | |
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | -30 K | Cash From Investing Activities | 4.37 M | Cash From Operating Activities | -5.95 M | Gross Profit | |
| Net Profit | -5.98 M | Operating Profit | -5.96 M | Total Assets | 32.32 M | Total Current Assets | 31.54 M |
| Total Current Liabilities | 3.13 M | Total Debt | 1000 K | Total Liabilities | 4.22 M | Total Revenue |
Technical Data
| High 52 week | 5.42 | Low 52 week | 0.26 | Last close | 0.34 | Last change | 0% |
| RSI | 57.14 | Average true range | 0.02 | Beta | 1.69 | Volume | 6.13 M |
| Simple moving average 20 days | 1.8% | Simple moving average 50 days | 3.03% | Simple moving average 200 days | -74.64% |
Performance Data
| Performance Week | 6.25% | Performance Month | -12.82% | Performance Quart | 6.25% | Performance Half | -71.9% |
| Performance Year | -90.03% | Performance Year-to-date | -91.39% | Volatility daily | 4.44% | Volatility weekly | 9.94% |
| Volatility monthly | 20.36% | Volatility yearly | 70.53% | Relative Volume | 56874.5% | Average Volume | 711.61 K |
| New High | New Low |
News
2020-05-18 08:00:10 | Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
2020-05-14 08:00:10 | Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
2020-05-11 08:00:10 | Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
2020-05-07 16:05:10 | The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
2020-05-01 16:05:10 | Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update
2020-04-20 08:00:10 | Histogen Announces Investigational Device Exemption Application for HST 002
2020-04-15 08:00:10 | Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program
2020-04-06 08:00:10 | Histogen Announces Investigational New Drug Application Amendment for HST 001
2020-03-11 16:45:10 | Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update
2020-02-06 08:00:00 | Histogen to Present at BIO CEO & Investor Conference
2020-01-28 16:05:10 | Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement
2019-12-02 09:04:02 | Intercept ICPT Gains 7.5% YTD on Progress in NASH Space
2019-11-29 08:41:01 | NASH Scorecard Year to Date: The Winners and the Losers
2019-11-18 16:05:00 | Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member
2019-11-05 19:15:12 | Conatus Pharmaceuticals CNAT Reports Q3 Loss, Misses Revenue Estimates
2019-11-05 16:05:00 | Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results
2019-11-03 08:22:39 | Is Conatus Pharmaceuticals Inc.'s NASDAQ:CNAT CEO Paid Enough Relative To Peers?
2019-10-31 10:35:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2019-10-11 12:02:04 | Phibro PAHC Suffers Dismal Segmental Sales, Margin Woes
2019-10-11 09:59:01 | Penumbra Enrolls First Patient for Study on Coronary Vessels
2019-09-19 10:29:52 | How Long Will Conatus Pharmaceuticals Inc.'s NASDAQ:CNAT Cash Last?
2019-09-10 09:21:01 | Top Ranked Momentum Stocks to Buy for September 10th
2019-08-19 09:00:01 | Conatus CNAT Upgraded to Strong Buy: Here's What You Should Know
2019-08-07 11:00:03 | Conatus CNAT Beats on Q2 Earnings, Stops Emricasan Studies
2019-08-06 19:25:11 | Conatus Pharmaceuticals CNAT Reports Q2 Loss, Tops Revenue Estimates
2019-08-06 16:05:00 | Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates
2019-07-31 10:36:02 | Will Conatus Pharmaceuticals CNAT Report Negative Q2 Earnings? What You Should Know
2019-07-25 13:46:33 | Investors Who Bought Conatus Pharmaceuticals NASDAQ:CNAT Shares Five Years Ago Are Now Down 96%
2019-06-26 16:17:31 | Conatus CNAT Stock Price Could Hit Zero
2019-06-26 08:37:12 | Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
2019-06-26 07:19:56 | The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
2019-06-26 06:07:10 | Conatus' Emricasan Lags Primary Goal in Liver Function Study
2019-06-25 11:32:45 | NASH Disappointment Forces Conatus To Explore Strategic Alternatives
2019-06-24 17:00:34 | UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial
2019-06-24 16:19:19 | Conatus Pharma to explore options, liver disease drug fails trial
2019-06-24 16:06:00 | Conatus to Explore Strategic Alternatives and Implement Restructuring Plan
2019-06-24 16:05:00 | Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
2019-06-12 18:27:10 | CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
2019-06-01 09:31:01 | Conatus CNAT Down 5.8% Since Last Earnings Report: Can It Rebound?
2019-05-28 11:48:03 | Conatus Down More Than 60% in the Past 90 Days: Here's Why
2019-05-24 09:39:55 | How Many Conatus Pharmaceuticals Inc. NASDAQ:CNAT Shares Do Institutions Own?
2019-05-06 14:53:06 | Conatus' CNAT Earnings, Revenues Miss Estimates in Q1
2019-05-02 19:15:11 | Conatus Pharmaceuticals CNAT Reports Q1 Loss, Lags Revenue Estimates
2019-05-02 18:11:35 | Conatus: 1Q Earnings Snapshot
2019-04-30 07:30:00 | Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis
2019-04-24 10:33:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2019-04-15 07:30:00 | Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
2019-04-07 09:30:01 | Why Is Conatus CNAT Down 37.8% Since Last Earnings Report?
2019-04-02 07:30:00 | Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference